Description of the CD133+ subpopulation of the human ovarian cancer cell line OVCAR3

Oncology Reports

Volumn 25, Issue 1, 2011, Pages 141-146

  Guo, Rongjiao ^a   Wu, Qiuhua ^a   Liu, Fenghua ^a   Wang, Yifeng ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

CD133; MicroRNAs; Ovarian cancer

Indexed keywords

CD133 ANTIGEN; MICRORNA; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; TUMOR MARKER;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL SELECTION; CELL SUBPOPULATION; CONTROLLED STUDY; CYTOMETRY; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; OVARY CANCER; OVCAR3 CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; VALIDATION PROCESS; WESTERN BLOTTING;

ANTIGENS, CD; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SEPARATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; MICROARRAY ANALYSIS; MICRORNAS; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; PEPTIDES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 78650756162     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00001053     Document Type: Article

References (29)

1. Curley MD, Therrien VA, Cummings CL, et al: CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 27: 2875-2883, 2009.
2. Baba T, Convery PA, Matsumura N, et al: Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 28: 209-218, 2009.
3. Kusumbe AP, Mali AM and Bapat SA: CD133-expressing stem cells associated with ovarian metastases establish an endothelial hierarchy and contribute to tumor vasculature. Stem Cells 27: 498-508, 2009.
4. Ferrandina G, Martinelli E, Petrillo M, Prisco MG, Zannoni G, Sioletic S and Scambia G: CD133 antigen expression in ovarian cancer. BMC Cancer 9: 221, 2009.
5. Rho JY, Yu K, Han JS, et al: Transcriptional profiling of the developmentally important signalling pathways in human embryonic stem cells. Hum Reprod 21: 405-412, 2006.
6. Ponnusamy MP and Batra SK: Ovarian cancer: emerging concept on cancer stem cells. J Ovarian Res 1: 4, 2008.
7. Pan Y and Huang X: Epithelial ovarian cancer stem cells: A review. Int J Clin Exp Med 1: 260-266, 2008.
8. Zhang L, Huang J, Yang N, et al: microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA 103: 9136-9141, 2006.
9. Korpal M, Lee ES, Hu G and Kang Y: The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 283: 14910-14914,2008.
10. Dahiya N, Sherman-Baust CA, Wang TL, et al: MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One 3: e2436, 2008.
11. Wyman SK, Parkin RK, Mitchell PS, et al: Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One 4: e5311, 2009.
12. Sotomayor P, Godoy A, Smith GJ and Huss WJ: Oct4A is expressed by a subpopulation of prostate neuroendocrine cells. Prostate 69: 401-410, 2009.
13. Bild AH, Yao G, Chang JT, et al: Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439: 353-357, 2006.
14. Evans PM and Liu C: Roles of Krupel-like factor 4 in normal homeostasis, cancer and stem cells. Acta Biochim Biophys Sin (Shanghai) 40: 554-564, 2008.
15. Schoenhals M, Kassambara A, De Vos J, Hose D, Moreaux J and Klein B: Embryonic stem cell markers expression in cancers. Biochem Biophys Res Commun 383: 157-162, 2009.
16. Wellner U, Schubert J, Burk UC, et al: The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 11: 1487-1495, 2009.
17. Iorio MV, Visone R, Di Leva G, et al: MicroRNA signatures in human ovarian cancer. Cancer Res 67: 8699-8707, 2007.
18. Henson BJ, Bhattacharjee S, O'Dee DM, Feingold E and Gollin SM: Decreased expression of miR-125b and miR-100 in oral cancer cells contributes to malignancy. Genes Chromosomes Cancer 48: 569-582, 2009.
19. Laios A, O'Toole S, Flavin R, et al: Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer 7: 35, 2008.
20. Krichevsky AM, Sonntag KC, Isacson O and Kosik KS: Specific microRNAs modulate embryonic stem cell-derived neurogenesis. Stem Cells 24: 857-864, 2006.
21. Johnnidis JB, Harris MH, Wheeler RT, et al: Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature 451: 1125-1129, 2008.
22. Huang J, Zhao L, Xing L and Chen D: MicroRNA-204 regulates Runx2 protein expression and mesenchymal progenitor cell differentiation. Stem Cells 28: 357-364, 2010.
23. Song G, Zhang Y and Wang L: MicroRNA-206 targets notch3, activates apoptosis, and inhibits tumor cell migration and focus formation. J Biol Chem 284: 31921-31927, 2009.
24. Liu Y and Labosky PA: Regulation of embryonic stem cell selfrenewal and pluripotency by Foxd3. Stem Cells 26: 2475-2484, 2008.
25. Nichols J, Zevnik B, Anastassiadis K, et al: Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell 95: 379-391, 1998.
26. Loh YH, Wu Q, Chew JL, et al: The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat Genet 38: 431-440, 2006.
27. Wang Q, He W, Lu C, et al: Oct3/4 and Sox2 are significantly associated with an unfavorable clinical outcome in human esophageal squamous cell carcinoma. Anticancer Res 29: 1233-1241, 2009.
28. Kola I, Brookes S, Green AR, Garber R, Tymms M, Papas TS and Seth A: The Ets1 transcription factor is widely expressed during murine embryo development and is associated with mesodermal cells involved in morphogenetic processes such as organ formation. Proc Natl Acad Sci USA 90: 7588-7592, 1993.
29. Ben-Shushan E, Thompson JR, Gudas LJ and Bergman Y: Rex-1, a gene encoding a transcription factor expressed in the early embryo, is regulated via Oct-3/4 and Oct-6 binding to an octamer site and a novel protein, Rox-1, binding to an adjacent site. Mol Cell Biol 18: 1866-1878, 1998.